Abivax’s lead candidate, ABX464, is gearing up to launch a Phase III program this year in about 1,400 patients with moderate-to-severe ulcerative colitis (UC). The company has held an end-of-Phase II meeting with the FDA and received scientific feedback from the European Medicines Agency. Both agencies supported ABX464 advancing into Phase III. Abivax’s treatments are designed to modulate the body’s inflammation and immunological pathways . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Inflection Point: Abivax Challenges Pharma Giants in Ulcerative Colitis appeared first on GEN – Genetic Engineering and Biotechnology News.
